NCT02685020 is a Phase 1 clinical trial of Ad26.Mos.HIV in Healthy, sponsored by Janssen Vaccines & Prevention B.V..

Who is sponsoring NCT02685020?

NCT02685020 is sponsored by Janssen Vaccines & Prevention B.V..

What drugs are being tested in NCT02685020?

Interventions in NCT02685020: Ad26.Mos.HIV, Clade C gp140, Placebo.

Is NCT02685020 still recruiting?

NCT02685020 is currently completed. Last updated 3 February 2025.

Last reviewed 2025-02-03 · How we verify

NCT02685020

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

Completed Phase 1 Last updated 3 February 2025

What this trial tests

Phase 1 trial testing Ad26.Mos.HIV in Healthy in 36 participants. Completed in 3 January 2019.

Timeline

28 March 2016

Primary endpoint
5 January 2018

3 January 2019

Quick facts

Lead sponsor	Janssen Vaccines & Prevention B.V.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	36
Start date	28 March 2016
Primary completion	5 January 2018
Estimated completion	3 January 2019
Sites	1 location across United States

Drugs / interventions tested

Ad26.Mos.HIV — full drug profile →
Clade C gp140 — full drug profile →
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Janssen Vaccines & Prevention B.V. — full company profile →

Who can join

Adults 18 to 50, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this study is to assess safety, tolerability of the different vaccine schedules (different regimen durations and different number of dose administrations) with Ad26.Mos.HIV and Clade C Glycoprotein (gp) 140 and to assess Envelope (Env)-binding Antibody (Ab) responses of the different vaccine schedules.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Progress in HIV vaccine development.
Hsu DC, O'Connell RJ. · · 2017 · cited 62× · PMID 28281871 · DOI 10.1080/21645515.2016.1276138
Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.
Custers J, Kim D, Leyssen M, Gurwith M, et al · · 2021 · cited 59× · PMID 33676782 · DOI 10.1016/j.vaccine.2020.09.018
New concepts in HIV-1 vaccine development.
Stephenson KE, D'Couto HT, Barouch DH. · · 2016 · cited 58× · PMID 27268856 · DOI 10.1016/j.coi.2016.05.011
Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
Stephenson KE, Wegmann F, Tomaka F, Walsh SR, et al · · 2020 · cited 21× · PMID 32078815 · DOI 10.1016/s2352-3018(20)30001-1
The Question of HIV Vaccine: Why Is a Solution Not Yet Available?
Libera M, Caputo V, Laterza G, Moudoud L, et al · · 2024 · cited 9× · PMID 38628675 · DOI 10.1155/2024/2147912

Verify or expand the search:

Other trials of Ad26.Mos.HIV

Trials testing the same drug.

NCT02788045 — Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad2 · Phase 1, PHASE2 · completed
NCT02315703 — Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mo · Phase 1, PHASE2 · completed

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Janssen Vaccines & Prevention B.V. trials

Trials by the same sponsor.

NCT05901636 — A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults · Phase 1, PHASE2 · completed
NCT05327816 — A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Year · Phase 1, PHASE2 · terminated
NCT05091307 — A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults · Phase 3 · completed
NCT05101486 — A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years · Phase 3 · completed
NCT05083585 — A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Ag · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02685020 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Vaccines & Prevention B.V.
Last refreshed: 3 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02685020.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing